Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: Final results of PRODIGE 23 phase III trial, a UNICANCER GI trial.
Thierry Conroy(Inserm), Christophe Borg(Centre Hospitalier Universitaire de Besançon), Éric Rullier(Bordeaux Population Health), Najib Lamfichekh(L'Hôpital Nord Franche-Comté), Clotilde Morand(Roche (France)), D. Gargot, V. Vendrely(Centre Hospitalier Universitaire de Bordeaux), Valérie Boige(Inserm), Nathalie Mesgouez‐Nebout(Institut de Cancérologie de l'Ouest), Xavier Artignan(Centre Hospitalier privé Saint Grégoire), Nathalie Bonichon-Lamichhane, Éric François(Centre Antoine Lacassagne), Pierre-Luc Etienne, Christelle de la Fouchardière(Aix-Marseille Université), Olivier Bouché(CHU Dijon Bourgogne), Béata Juzyna(Université Paris Cité), Emmanuel Rio(Institut de Cancérologie de l'Ouest), Florence Castan(Université de Montpellier), Frédéric Marchal(Institut de Cancérologie de Lorraine), Christophe Louvet(Institute Mutualiste Montsouris)
Cited by 177
Related Papers
Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.8k
Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
|Journal of Clinical Oncology|2011|2.1k
Preoperative Radiotherapy With or Without Concurrent Fluorouracil and Leucovorin in T3-4 Rectal Cancers: Results of FFCD 9203
|Journal of Clinical Oncology|2006|1.7k
Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.3k